Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

An IFNγ-Mediated Immune Inflamed Microenvironment State in Multiple Myeloma with TP53 Loss That Can be Therapeutically Exploited

Blood (2024) 144 (Supplement 1): 670.

https://doi.org/10.1182/blood-2024-194041

Published: 2024

Journal Articles

The PP2A-B56α Heterocomplex Regulates Response to Venetoclax Plus Azacitidine Treatment in AML

Silvia Romero-Murillo, Irene Peris, Nerea Marcotegui, Carmen Vicente, Maria D. Odero, Goutham Narla

Blood (2023) 142 (Supplement 1): 2784.

https://doi.org/10.1182/blood-2023-174496

Published: 2023

Journal Articles

Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation

Irene Peris, Silvia Romero-Murillo, Elena Martínez-Balsalobre, Caroline C. Farrington, Elena Arriazu, Nerea Marcotegui, Marta Jiménez-Muñoz, Cristina Alburquerque-Prieto, Andrea Torres-López, Vicente Fresquet, Jose A. Martínez-Climent, Maria C. Mateos, Maria L. Cayuela, Goutham Narla, Maria D. Odero, Carmen Vicente

Blood (2023) 141 (9): 1047–1059.

https://doi.org/10.1182/blood.2022016466

Published: 2023

Includes: Supplemental data

Journal Articles

Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia

Michael Broux, Cristina Prieto, Sofie Demeyer, Marlies Vanden Bempt, Llucia Alberti-Servera, Inge Lodewijckx, Roel Vandepoel, Nicole Mentens, Olga Gielen, Kris Jacobs, Ellen Geerdens, Carmen Vicente, Charles E. de Bock, Jan Cools

Blood (2019) 134 (16): 1323–1336.

https://doi.org/10.1182/blood.2019000015

Published: 2019

Includes: Supplemental data

Journal Articles

The genetics and molecular biology of T-ALL

Tiziana Girardi, Carmen Vicente, Jan Cools, Kim De Keersmaecker

Blood (2017) 129 (9): 1113–1123.

https://doi.org/10.1182/blood-2016-10-706465

Published: 2017

Journal Articles

Hedgehog pathway activation in T-cell acute lymphoblastic leukemia predicts response to SMO and GLI1 inhibitors

Antonis Dagklis, Sofie Demeyer, Jolien De Bie, Enrico Radaelli, Daphnie Pauwels, Sandrine Degryse, Olga Gielen, Carmen Vicente, Roel Vandepoel, Ellen Geerdens, Anne Uyttebroeck, Nancy Boeckx, Charles E. de Bock, Jan Cools

Blood (2016) 128 (23): 2642–2654.

https://doi.org/10.1182/blood-2016-03-703454

Published: 2016

Includes: Supplemental data

Journal Articles

JAK3 Mutants Transform Hematopoietic Cells through JAK1 Activation Causing T-Cell Acute Lymphoblastic Leukemia in a Bone Marrow Transplant Mouse Model

Degryse Sandrine, Charles E de Bock, PhD, Carmen Vicente, PhD, Luk Cox, PhD, Olga Gielen, Nicole Mentens, Kris Jacobs, Ellen Geerdens, Thomas Tousseyn, PhD, Jan Cools, PhD

Blood (2014) 124 (21): 361.

https://doi.org/10.1182/blood.V124.21.361.361

Published: 2014

Journal Articles

Functional Analysis of the GATA2 Promoter Shows That Mutations of GATA2 Impair Its Own Transcriptional Regulation

Xabier Cortes-Lavaud, M.Sc., Miren Maicas, Ph.D., Iria Vazquez, Ph.D., Carmen Vicente, Ph.D., Leire Urquiza, M.Sc., Maria A Garcia-Sanchez, Ph.D., Maria D Odero, MD, Ph.D.

Blood (2012) 120 (21): 1233.

https://doi.org/10.1182/blood.V120.21.1233.1233

Published: 2012

Journal Articles

Non- IG Aberrations of FOXP1 in B-Cell Malignancies Result in an Aberrant Expression of N-Truncated FOXP1 Isoforms.

Iwona Wlodarska, PhD, Leila Rouhi, MD, Julio Finalet Ferreiro, M Sc, Thomas Tousseyn, MD PhD, Natalie Put, MD, Eugenia Haralambieva, MD, PhD, Carlos Graux, MD, PhD, Brigitte Maes, MD, PhD, Carmen Vicente, PhD, Peter Vandenberghe, MD, PhD, Jan Cools, PhD

Blood (2012) 120 (21): 2411.

https://doi.org/10.1182/blood.V120.21.2411.2411

Published: 2012

Journal Articles

SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia

Ion Cristóbal, Francisco J. Blanco, Laura Garcia-Orti, Nerea Marcotegui, Carmen Vicente, José Rifon, Francisco J. Novo, Eva Bandres, María J. Calasanz, Carmelo Bernabeu, María D. Odero

Blood (2010) 115 (3): 615–625.

https://doi.org/10.1182/blood-2009-06-227363

Published: 2010

Includes: Supplemental data

Journal Articles

MYB Overexpression Is Directly Involved in Acute Myeloid Leukemia Pathogenesis and Could Constitute a New Therapeutic Target for Patients with Aberrant Expression of This Gene.

Carmen Vicente, Ph.D., Ana Conchillo, Ph.D., Daphnie Pauwels, BSc, Iria Vazquez, Ph.D., Laura Garcia-Orti, BSc, Maria J. Calasanz, Ph.D., Idoya Lahortiga, Ph.D., Jan Cools, Ph.D., Maria D. Odero, MD, Ph.D.

Blood (2009) 114 (22): 2402.

https://doi.org/10.1182/blood.V114.22.2402.2402

Published: 2009

Journal Articles

BMI1 , the Polycomb-Group Gene, Is Recurrently Targeted by Genomic Rearrangements in Progressive B-Cell Leukemia/Lymphoma.

Leila Rouhi, MD, Natalie Put, MD, Thomas Tousseyn, MD, PhD, Julio Finalet Ferreiro, Wim De Kelver, Hilde Demuynck, MD, Johan Verschuere, MD, Ivan Théate, MD, Carmen Vicente, Lucienne Michaux, MD, PhD, Chris De Wolf-Peeters, MD, PhD, Peter Vandenberghe, MD, PhD, Jan Cools, PhD, Iwona Wlodarska, PhD

Blood (2009) 114 (22): 1099.

https://doi.org/10.1182/blood.V114.22.1099.1099

Published: 2009

Journal Articles

A Gain of Function Mutation in JAK2 Is Frequently Found in Patients with AML-M2 and Normal Karyotype.

Nerea Marcotegui, BSc, Idoya Lahortiga, PhD, Iria Vazquez, BSc, Jose L. Vizmanos, PhD, Ion Cristobal, BSc, Cristina Ormazabal, BSc, Eva Bandres, PhD, Maria J. Larrayoz, BSc, Carmen Vicente, BSc, Maria J. Calasanz, PhD, María D. Odero, MD, PhD

Blood (2005) 106 (11): 2366.

https://doi.org/10.1182/blood.V106.11.2366.2366

Published: 2005

Journal Articles

GATA2 Is Overexpressed in 46% of Patients with AML and Normal Karyotype. The Mutational Pattern FLT3-ITD/GATA2/WT1 Could Define a Group of Patients with Normal Karyotype and AML-M1 Subtype.

Idoya Lahortiga, PhD, Iria Vazquez, BSc, Nerea Marcotegui, BSc, Eva Bandres, PhD, Raquel Malumbres, PhD, Maria J. Larrayoz, BSc, Carmen Vicente, BSc, Jose Cervera, MD, PhD, Jesus M. Hernandez, MD, PhD, Jesus Garcia-Foncillas, MD, PhD, Maria T. Ardanaz, MD, Filomena Floristan, MD, Maria J. Calasanz, PhD, Maria D. Odero, MD, PhD

Blood (2005) 106 (11): 2378.

https://doi.org/10.1182/blood.V106.11.2378.2378

Published: 2005

Journal Articles

GATA2 May Contribute with EVI1 to the Leukemogenic Mechanism in Patients with 3q21q26 Rearrangements.

Iria Vazquez, BSc, Idoya Lahortiga, PhD, Nerea Marcotegui, BSc, Maria Jose Larrayoz, BSc, Carmen Vicente, BSc, Jesus Maria Hernandez, MD, Jose Cervera, MD, Maria Jesus Vidal, MD, Jose A. Marquez, MD, Maria Jose Calasanz, PhD, Maria Dolores Odero, MD, PhD

Blood (2005) 106 (11): 2852.

https://doi.org/10.1182/blood.V106.11.2852.2852

Published: 2005

NARROW

An IFNγ-Mediated Immune Inflamed Microenvironment State in Multiple Myeloma with TP53 Loss That Can be Therapeutically Exploited

The PP2A-B56α Heterocomplex Regulates Response to Venetoclax Plus Azacitidine Treatment in AML

Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation

Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia

The genetics and molecular biology of T-ALL

Hedgehog pathway activation in T-cell acute lymphoblastic leukemia predicts response to SMO and GLI1 inhibitors

JAK3 Mutants Transform Hematopoietic Cells through JAK1 Activation Causing T-Cell Acute Lymphoblastic Leukemia in a Bone Marrow Transplant Mouse Model

Functional Analysis of the GATA2 Promoter Shows That Mutations of GATA2 Impair Its Own Transcriptional Regulation

Non- IG Aberrations of FOXP1 in B-Cell Malignancies Result in an Aberrant Expression of N-Truncated FOXP1 Isoforms.

SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia

MYB Overexpression Is Directly Involved in Acute Myeloid Leukemia Pathogenesis and Could Constitute a New Therapeutic Target for Patients with Aberrant Expression of This Gene.

BMI1 , the Polycomb-Group Gene, Is Recurrently Targeted by Genomic Rearrangements in Progressive B-Cell Leukemia/Lymphoma.

A Gain of Function Mutation in JAK2 Is Frequently Found in Patients with AML-M2 and Normal Karyotype.

GATA2 Is Overexpressed in 46% of Patients with AML and Normal Karyotype. The Mutational Pattern FLT3-ITD/GATA2/WT1 Could Define a Group of Patients with Normal Karyotype and AML-M1 Subtype.

GATA2 May Contribute with EVI1 to the Leukemogenic Mechanism in Patients with 3q21q26 Rearrangements.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only